Latest Intelligence on Central Nervous System in South and Central America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

Type Product title / description Pub Price
Expert View
Expert View

AAN 2010: late-stage pipeline candidates take center stage in migraine

In the wake of Imitrex's and Topamax's patent expiries, announcements at this year's American Academy of Neurology meeting focused firmly on the next major breakthroughs for the acute and prophylactic migraine markets. Pooled data for candidates from Allergan and Merck & Co demonstrated impressive potential, suggesting renewed hope for sufferers.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: new treatments address unmet needs in Alzheimer's and epilepsy

A number of leading drug makers used this year's meeting of the American Academy of Neurology to present new data for promising pipeline candidates. Despite promising results, however, Datamonitor believes that the epilepsy drugs will struggle to find their place in the market. Moreover, the positive Phase II data for Baxter's potential Alzheimer's therapy Gammagard do not guarantee later success.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: spotlight shines on Novartis' and Merck KGaA's oral MS candidates

Datamonitor attended this year's American Academy of Neurology conference, where developments in multiple sclerosis took precedence for the third consecutive year. Both Novartis and Merck KGaA presented new data for their pipeline candidates, while Acorda used the meeting as a platform to share data for its symptomatic treatment Ampyra, which was recently approved by the FDA.

Published By Datamonitor
20 Apr 2010
CommentWire
CommentWire

Actelion/GlaxoSmithKline: future of innovative orexin drug class in doubt

Actelion and GlaxoSmithKline have discontinued development of their Phase III insomnia candidate, almorexant, following a review of clinical data. The drug, an orexin receptor antagonist, had been widely regarded by leading sleep disorder specialists as an innovative and promising insomnia treatment. Termination of the drug's development casts doubt over the future of the drug class.

Published By Datamonitor
28 Jan 2011
Expert View
Expert View

AD/PD 2011: Alzheimer's companies showcase new data for marketed brands

Datamonitor recently attended the 10th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2011) in Barcelona, Spain, held over March 9-13, 2011. Below are the highlights of the conference's coverage of currently marketed treatments for both diseases.

Published By Datamonitor
24 Mar 2011
Expert View
Expert View

AD/PD 2011: far too early to lay beta-amyloid hypothesis to rest

Datamonitor recently attended the 10th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2011) in Barcelona, Spain, held over March 9-13, 2011. Below are the highlights of the conference's coverage of pipeline Alzheimer's drugs.

Published By Datamonitor
24 Mar 2011
ResearchWire
ResearchWire

ADHD: immature adult market continues to offer greatest commercial potential

Published By Datamonitor
14 May 2008
CommentWire
CommentWire

Amarin: RNA therapy results announced to attract suitors

In an effort to generate interest from potential partners in its investigational myasthenia gravis agent, EN101, Amarin has announced positive final efficacy data from an exploratory Phase IIa study. Although these promising data support a symptomatic effect, greater value could be expected if immunosuppressant activity is also demonstrated in later trials.

Published By Datamonitor
11 Jun 2009
ResearchWire
ResearchWire

Anxiety disorders: global sales set to slide

Published By Datamonitor
03 May 2006
CommentWire
CommentWire

APA 2010: Alkermes prepares to enter potentially lucrative opioid dependence market

At this year's American Psychiatric Association meeting, US pharmaceutical company Alkermes presented promising new data for Vivitrol in the treatment of opioid dependence. The FDA is currently assessing the drug under a priority review, and approval in the burgeoning opioid dependence indication would be a major boon for Alkermes.

Published By Datamonitor
10 Jun 2010

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

No help is available.